

## Compassionate Use Program

MEI Pharma, Inc. is an oncology-focused pharmaceutical company with investigational drug products being studied in clinical trials. Our investigational drug products target different mechanisms critical to overcoming cancer progression and drug resistance in various B-cell malignancies.

MEI Pharma's ongoing clinical trials are meant to determine if the investigational drug product being tested is safe and effective. Regulatory authorities (e.g., the Food and Drug Administration in the US) will make the final decision whether to approve the investigational drug product. This will be based on the clinical trial and other data that MEI will submit for review. Until the regulatory authority has made this decision, the investigational drug product remains experimental and is not available to the general public. However, there may be some instances in which individuals not enrolled in an MEI clinical trial may be interested in seeking a particular experimental treatment. In this circumstance, Compassionate Use (also known as Expanded Access) may be appropriate.

To learn more about clinical trials that are underway at MEI Pharma, please visit [www.clinicaltrials.gov](http://www.clinicaltrials.gov) and search by company name, disease, or investigational drug product.

### **What if I am interested in one of MEI's investigational drug products?**

A patient interested in being considered for receiving one of MEI's investigational drug products as part of MEI Pharma's Compassionate Use Program, should first discuss their medical options with their treating physician. Should the patient and physician decide to move forward, then the treating physician may contact the MEI Pharma team for possible patient consideration. The MEI Pharma team will evaluate each request on a case-by-case basis and notify the treating physician of their decision in as timely a manner as possible.

### **How does MEI Pharma determine whether to provide an experimental treatment to a patient under our Compassionate Use Program?**

The many factors that MEI Pharma will consider before determining if a patient should be provided access to the investigational drug product are:

- The patient has a serious and/or life-threatening disease or condition;
- No alternative therapies to treat the disease or condition are available;
- The patient does not qualify for any of the currently enrolling MEI clinical trials;
- The potential benefits of the investigational drug product outweigh the risk; and all other relevant medical criteria that would allow for use of the investigational drug product are met;
- There is adequate investigational drug product to supply the ongoing clinical trials and approved Compassionate Use until and if the product becomes commercially available;

- Compassionate Use is permitted in the country, region and/or state where the investigational drug product will be administered;
- The licensed treating physician has obtained all necessary regulatory/institutional approvals; and
- Any additional requirements set forth by law/regulation have been met.

## How do I make a request?

- A treating physician may click the link below to provide their contact information. A follow up email will be sent shortly to the physician to gather additional information.

<https://www.meipharma.com/compassionate-use-intake-form>

## For more information

MEI Pharma will consider each request carefully, fairly and in an unbiased manner. Once all necessary information has been received, the MEI Pharma team will notify the treating physician of their decision in as timely a manner as possible.

For more information on Compassionate Use, treating physicians may contact MEI Pharma's Compassionate Use team at [CompUse@meipharma.com](mailto:CompUse@meipharma.com)

For information on MEI Pharma's Privacy Policy, please refer to MEI Pharma's Privacy Notice (<https://www.meipharma.com/privacy-notice>)